Pfizer

Pfizer faces $1 billion charge in bogus patent dispute over blood pressure medication Norvasc

Sunday, September 09, 2012 by: Jonathan Benson, staff writer
Tags: Pfizer, patents, Jamaica

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
BACK INTO THE CLOSET: Why U.S. reporters are not allowed to write about rainbow events in nations where being gay is still condemned
Depopulation test run? 75% of children who received vaccines in Mexican town now dead or hospitalized
A family destroyed: Six-month-old dies after clinic injects baby with 13 vaccines at once without mother's informed consent
Biologist explains how marijuana causes tumor cells to commit suicide
Companies begin planting microchips under employees' skin
INVESTIGATION: Three days before Dr. Bradstreet was found dead in a river, U.S. govt. agents raided his research facility to seize a breakthrough cancer treatment called GcMAF
BAM! Chipotle goes 100% non-GMO; flatly rejecting the biotech industry and its toxic food ingredients
ECONOMIC SLAVERY FOR ALL: While we were distracted with the Confederate flag flap, Congress quietly forfeited our entire economic future via fast-track trade authority
NJ cops bust teenagers shoveling snow without a permit
Chemotherapy kills cancer patients faster than no treatment at all
McDonald's in global profit free fall as people everywhere increasingly reject chemically-altered toxic fast food
March Against Monsanto explodes globally... World citizens stage massive protests across 38 countries, 428 cities... mainstream media pretends it never happened
Italian court rules mercury and aluminum in vaccines cause autism: US media continues total blackout of medical truth
The 21 curious questions we're never allowed to ask about vaccines
SCOTUS same-sex marriage decision may have just legalized the concealed carry of loaded firearms across all 50 states, nullifying gun laws everywhere
Orthorexia Nervosa - New mental disorder aimed at people who insist on eating a clean diet
Vicious attack on Dr. Oz actually waged by biotech mafia; plot to destroy Oz launched after episode on glyphosate toxicity went viral
Nearly every mass shooting in the last 20 years shares one surprising thing? and it's not guns
Delicious
(NaturalNews) Several years ago, drug giant Pfizer Inc. tried to pull a fast one in Jamaica where several local companies were legally distributing generic versions of Pfizer's formerly-patented blood pressure drug Norvasc (Amlodipine). Though the drug was already off-patent elsewhere, Pfizer still tried to sue the distributors in Jamaica for patent infringement, and is now being summoned to fork over about $1 billion for compensation and legal costs for this foolish move.

On January 22, 2007, Pfizer reportedly obtained a patent for Norvasc in Jamaica, despite the fact that the same patent for the drug had already expired in Egypt about a decade earlier on March 31, 1997. Jamaica's Patents Act of 1857 prohibits the patenting of a drug that has already had its patent expire in another country, which means Pfizer's attempt to re-patent Norvasc was technically invalid and illegal.

But according to the Jamaica Gleaner, Pfizer decided to take both Lasco and Medimpex, the two companies involved, to court back in 2002 in an attempt to thwart their distribution system. And in the process, Pfizer successfully obtained an injunction in 2005 forcing the companies to stop distributing the drug.

The case was eventually taken to the Supreme Court; however, where Justice Roy Jones, now retired, ruled that Pfizer's Jamaica patent for Norvasc was null. Pfizer responded by trying to appeal the decision on the grounds that Justice Jones had erred in his understanding of the law. But the Court of Appeals unanimously affirmed several years later that the decision was valid, and that Pfizer's Jamaican patent for Norvasc was in violation of the law.

In their own defense, Lasco and Medimpex explained that details about Norvasc's ingredients and formulation had already been openly publicized in journals since as far back as October 1986. This, of course, is in addition to the fact that Norvasc had been made legally available for generic production and distribution for about 15 years.

Just a few weeks before Pfizer was hit with the $1 billion charge in the Norvasc case, the company also settled a lawsuit involving its painkiller drug Celebrex. The New York Times reports that Pfizer agreed to pay $450 million to settle charges filed against it by Brigham Young University in Utah, which accused the company of violating a research agreement it had made with the university over its role in originally developing the drug.

Sources for this article include:

http://jamaica-gleaner.com/latest/article.php?id=37535

http://www.jamaicaobserver.com

http://www.nytimes.com

Follow real-time breaking news headlines on
Pfizer at FETCH.news
Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.